ATC Group: N02CC01 Sumatriptan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02CC01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02C Antimigraine preparations
4 N02CC Selective serotonin (5HT1) agonists
5 N02CC01 Sumatriptan

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
NASAL - Nasal 20 mg
ORAL - Oral 50 mg
PAREN - Parenteral 6 mg
RECTAL - Rectal 25 mg

Active ingredients in N02CC01

Active Ingredient Description
Sumatriptan

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction.

Related product monographs

Title Information Source Document Type  
IMIGRAN Nasal spray, solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMIGRAN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMIGRAN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMITREX Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
IMITREX Nasal spray FDA, National Drug Code (US) MPI, US: SPL/PLR
IMITREX Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
SUMATRAN Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.